Search Results 711-720 of 17411 for alopecia
... . VID-20466619. Home; Jessica's Story. Double your impact on cancer! Give Now. Make a gift before July 31 and it can be doubled in impact thanks to a ...
Recovery to ≤ Grade 1 or baseline of any non-hematological toxicities due to previous therapy, except alopecia and peripheral neuropathy. Agree to refrain ...
alopecia. Exclusion Criteria: - Tumors in the breast or bone - Untreated central nervous system (CNS) metastases. Subjects requiring corticosteroid therapy ...
... alopecia) due to therapy administered prior to the initiation of study drug dosing. Nursing or pregnant. Known allergy or hypersensitivity to any of the ...
You'll receive your Mayo Clinic email newsletter starting with the next issue. Share · Tweet . ART-20051269. Home; Subscription Confirmation.
Each person's genetic code is unique. Researchers focused on pharmacogenomics at Mayo Clinic are working to understand how these tiny DNA variations cause ...
EXCEPTIONS: Stable chronic conditions (≤ grade 2) that are not expected to resolve (such as neuropathy, myalgia, alopecia, prior therapy-related ...
In addition, any drug-related toxicity except alopecia should have recovered to Grade 1 or less. Prior therapy with any ERK inhibitor (e.g., LY3214996 ...
Subjects with ≤Grade 2 neuropathy and ≤Grade 2 alopecia are an exception to this criterion and may qualify for therapy. Note: If participant received ...
... alopecia, related to anticancer therapy prior to the first dose of study drug; Major medical conditions that might affect EAP participation (e.g. ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift before July 31 and it can be doubled in impact thanks to a $100,000 Summer Challenge.